ClinicalTrials.govpublic full text
Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients
human epidermal growth factor 2 negative carcinoma of breast
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 230357
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.